They aimed at establishing whether curcumin influenced the duration of treatment interruption and rate of prostatic specific antigen (PSA) progression, compared with placebo, among men with prostate cancer receiving intermittent androgen deprivation therapy. The gene discussed is KLK3; the disease is prostate cancer.